Search

Displaying results 1721 - 1730 of 10000 in total
  1. Drug

    Atidarsagene autotemcel

    go.drugbank.com/drugs/DB17538
    ApprovedInvestigational

    [L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic … [L45196] It was granted FDA approval under the brand name Lenmeldy in March 2024.[L50256]

  2. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning in adult patients for whom a suitable donor is not

  3. Drug

    Antrafenine

    go.drugbank.com/drugs/DB01419
    Approved

    It is not widely used as it has largely been replaced by newer drugs.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Non COX-2 selective NSAIDS
  4. Drug

    Diloxanide

    go.drugbank.com/drugs/DB08792
    Experimental

    Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990. … Diloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections.

  5. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    While these patients have a median survival of approximately 4 months and a poor prognosis [L1396], there is currently no standard therapy in patients with advanced urothelial carcinoma [A32626]. … Efficacy and safety of vinflunine has not been studied in patients with performance status of 2 or less.

  6. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection. … Patients with AHA have normal Factor VIII genes for coagulation pathways but develop inhibitory autoantibodies directed against Factor VIII.

  7. Drug

    Thiosulfuric acid

    go.drugbank.com/drugs/DB09499
    ApprovedInvestigational

    Thiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate. Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, ...

  8. Drug

    Spironolactone

    go.drugbank.com/drugs/DB00421
    ApprovedInvestigational

    [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]

  9. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. … As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28].

  10. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]